Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
about
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerClinical implementation of pharmacogeneticsLiquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoringCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Liquid biopsy genotyping in lung cancer: ready for clinical utility?Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer.Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significanceCorrelation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implicationsAnalyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day.Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung CancerIntegrated digital error suppression for improved detection of circulating tumor DNABase-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review.Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer.Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer.Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase InhibitorsPlasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted SequencingSerial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trialEGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistanceConcordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.Circulating DNA in solid organ cancers-analysis and clinical application.Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.Liquid Biopsy in Non-Small Cell Lung Cancer.The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.Integrating liquid biopsies into the management of cancer.
P2860
Q26741318-AFCBCA02-939D-4F1A-B02E-6BC4B70E0D9DQ26775376-5A2EECB0-F0E2-48BF-9D63-E87207C15928Q26801357-A7AE9E80-DA4C-48DA-891E-A84E312BB44CQ28072159-99F0EACE-CF2B-4BF2-8056-62885C9281E2Q28076191-F781BD9C-479B-4242-8168-1DE99B3B41CDQ28077340-58111461-1F0B-4F55-8C8A-2A7C9CD3B0FBQ33567037-2344BCC4-62ED-4519-B651-2EB4F7678F88Q33598423-45F21AD3-DD75-4BF7-903E-E81A3EC3C3ECQ33751216-FE3F6E72-4623-4FA1-B276-08EEEF3E1879Q33779585-E3F82CFF-ABA3-4FF3-BD02-9251BD7D55ECQ33863388-B0861543-2DDB-417B-BE74-6EEAA5D293E8Q33873095-6008E3EB-C213-4B44-8C81-0107DACCB1F9Q34520008-F5277CEB-403F-4BC7-B494-9AD0CF8B6A20Q36233903-DA2F18CC-F95B-498E-866B-E97D8908F6BCQ36277022-2D890ECD-CE23-4EFA-A4DE-9A8310C76700Q36278010-0F6C4DBB-C774-4096-BEDD-AD7D19475221Q36378903-602DD9C2-6259-4E64-B3E1-CF717ECD92D4Q36558400-3534A972-CD8E-4671-8A86-8249CA8C2D9EQ36574146-12EDE625-D113-41BB-A321-145F955EE66BQ36643142-3C064ADB-5048-4403-A863-30469D565B5FQ36844366-F7E9295A-7876-4F53-B593-F2E4C51E1C55Q36916399-432527D7-F160-4227-B75C-C48A3F1AC451Q37000646-1A55A32A-4982-4C96-957C-8F3B4195D53CQ37190448-08AA917B-D6CB-4099-BDF8-273DA560FCF2Q37198902-1AB7F251-EF59-4F9F-8A68-5FAE49B1EC4CQ37251422-7C9EA71E-2C9E-4890-9BBB-F7031023DCABQ37592893-FAA102BC-14A6-45CF-895F-EB9731F0D90AQ37609221-6FA7C3D2-3439-433A-A0A5-8A7C105DD2BBQ37662237-41CFD29F-FE35-45B0-A361-28DFBDFCAAD3Q37690677-2FC3AA1D-4439-4E66-959E-920BEACA1C64Q37701499-D6A0E08E-1FB8-4552-AD2D-AEBCCE199F39Q38376337-750E3ED1-4FBF-49D1-B88F-9D448F0AC9DFQ38580327-2E8B4005-01D8-4DA5-B57E-400B3C1D473CQ38694431-B149A992-12DF-49E4-AC35-DDCDFF615253Q38772190-BE0C7867-8DBA-4447-BE27-1CDB79704AC7Q38844281-2DDDB2F8-83F8-4B38-AA14-3430B695FD7DQ39045171-23F4574A-FDAC-47EB-A27A-DCB782023E3EQ39076207-0DB797F4-B8BE-4E2F-9AC5-E14CBED0E7F7Q39097813-06F8E463-D46D-4746-8AA8-3EB6761CB12AQ39157824-5F6D1E16-6DEE-47D9-8F5C-E2D7C7CFFF43
P2860
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Detection and Dynamic Changes ...... ed Erlotinib and Chemotherapy.
@ast
Detection and Dynamic Changes ...... ed Erlotinib and Chemotherapy.
@en
type
label
Detection and Dynamic Changes ...... ed Erlotinib and Chemotherapy.
@ast
Detection and Dynamic Changes ...... ed Erlotinib and Chemotherapy.
@en
prefLabel
Detection and Dynamic Changes ...... ed Erlotinib and Chemotherapy.
@ast
Detection and Dynamic Changes ...... ed Erlotinib and Chemotherapy.
@en
P2093
P1476
Detection and Dynamic Changes ...... ted Erlotinib and Chemotherapy
@en
P2093
Barbara Klughammer
Benjamin Margono
Caicun Zhou
David S Shames
Fatima Fuerte
Guia Ladrera
Jennifer Sandoval-Tan
Jin Soo Lee
Julie Tsai
P304
P356
10.1158/1078-0432.CCR-14-2594
P407
P577
2015-03-31T00:00:00Z